BioSpace News Archive

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced clinical data from a Phase 1 study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin (AAT) deficiency

The Pennsylvania Department of Military and Veterans Affairs (DMVA) has extended the deadline for the 2018-19 Veterans’ Trust Fund (VTF) grant cycle

Companies specializing in medical devices, digital health, and therapeutics were among the 59 companies that presented their four-minute business plan presentations at the Texas Life Science Forum hosted by the Rice Alliance for Technology and Entrepreneurship and BioHouston and TMC Innovation at the BioScience Research Collaborative in Houston, Nov. 8.

Partnership creates affordable homeownership in North Chicago

The number of tick-borne related illnesses have increased significantly in the last decade. According to the CDC, there has been a three-fold increase in disease cases from infected mosquitos, ticks and fleas in the US from 2004 to 2016.

IBBL (Integrated BioBank of Luxembourg) celebrates this quarter the 10th anniversary of its creation.

On behalf of the Honourable Ginette Petitpas Taylor, federal Minister of Health, the Honourable Ralph Goodale, Minister of Public Safety and Emergency Preparedness, and the Honourable Jim Reiter, Minister of Health, Province of Saskatchewan, will announce new measures to increase access to treatment for substance use disorder.

The U.S. Food and Drug Administration today announced that, on behalf of the agency, the U.S. Marshals Service has conducted a mass seizure of FDA-regulated products that were being held under insanitary conditions in which they were exposed to widespread rodent, insect and live animal infestation.

Phase 2 Data Presented on Investigational FXR Agonist GS-9674 in NASH

In Post-Hoc Pooled Analysis of North American Studies, Investigational Agent Terlipressin Associated With Improvement in Survival in Patients with Hepatorenal Syndrome Type 1 with Low Baseline Mean Arterial Pressure